» Authors » Amy Gallo

Amy Gallo

Explore the profile of Amy Gallo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 709
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedman Ross L, Gallo A, Hester D
Am J Bioeth . 2024 Sep; 24(10):115-117. PMID: 39283371
No abstract available.
2.
Mullis D, Garrison A, Heng E, Zhu Y, Elde S, Nilkant R, et al.
J Thorac Cardiovasc Surg . 2024 Aug; PMID: 39187122
Background: Combined heart-liver transplantation (CHLT) is a definitive therapy reserved for patients with concomitant heart failure and advanced liver disease. A limited number of centers perform CHLT, and even fewer...
3.
Levitte S, Nilkant R, Chen S, Beadles A, Lee J, Bonham C, et al.
Transplant Direct . 2024 Aug; 10(9):e1696. PMID: 39165490
Background: Combined heart liver transplant (CHLT) continues to gain attention as a surgical treatment for patients with end-stage heart and liver disease but remains rare. We present our institutional longitudinal...
4.
White M, Ross L, Gallo A, Parker W
Transplantation . 2024 May; 108(10):2127-2133. PMID: 38773845
Background: The US Kidney Allocation System allocates en bloc deceased donor kidney grafts from donors <18 kg in sequence A along with single kidney transplants (SKTs) from kidney donor profile...
5.
Sedki M, Kwong A, Bhargava M, Ahmed A, Daugherty T, Kwo P, et al.
Transplantation . 2023 Oct; 108(3):742-749. PMID: 37899485
Background: The selection of liver transplant (LT) candidates with alcohol-related liver disease (ALD) is influenced by the risk of alcohol relapse (AR), yet the ability to predict AR is limited....
6.
Ahn D, Zeng S, Pelzer K, Barth R, Gallo A, Parker W
Transplantation . 2023 Jul; 107(10):e247-e256. PMID: 37408100
Background: In the United States, over half of pediatric candidates receive exceptions and status upgrades that increase their allocation model of end-stage liver disease/pediatric end-stage liver disease (MELD/PELD) score above...
7.
Sigurjonsdottir V, Purington N, Chaudhuri A, Zhang B, Fernandez-Vina M, Palsson R, et al.
Transpl Int . 2022 Aug; 35:10158. PMID: 35992747
Antibody-mediated rejection is a common cause of early kidney allograft loss but the specifics of antibody measurement, therapies and endpoints have not been universally defined. In this retrospective study, we...
8.
Piburn K, Sigurjonsdottir V, Indridason O, Maestretti L, Patton M, McGrath A, et al.
Clin J Am Soc Nephrol . 2022 Jul; 17(8):1194-1203. PMID: 35882506
Background And Objectives: High tacrolimus intrapatient variability has been associated with inferior graft outcomes in patients with kidney transplants. We studied baseline patterns of tacrolimus intrapatient variability in pediatric patients...
9.
Bekki Y, Kozato A, Kusakabe J, Tajima T, Fujiki M, Gallo A, et al.
Clin Transplant . 2022 Jul; 36(9):e14778. PMID: 35866342
Background: During the donor hepatectomy time (dHT), defined as the time from the start of cold perfusion to the end of the hepatectomy, liver grafts have a suboptimal temperature. The...
10.
Bertaina A, Grimm P, Weinberg K, Parkman R, Kristovich K, Barbarito G, et al.
N Engl J Med . 2022 Jun; 386(24):2295-2302. PMID: 35704481
Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune...